

100013 N.E. Hazel Dell Avenue  
Suite 317  
Vancouver, WA 98685

Telephone: (503) 806-3533

Email: [vic@vicdevlaeminck.com](mailto:vic@vicdevlaeminck.com)

November 9, 2024

OTC Markets Group, Inc.  
300 Vesey Street, 12<sup>th</sup> Floor  
New York, NY 10282

RE: Medican Enterprises, Inc. ("Issuer")

Dear Sir or Madam:

I represent Medican Enterprises, Inc., (Symbol: MDCN), a Nevada corporation (the "Issuer") as its legal counsel. My client has requested that I render a legal opinion as to whether there is adequate current information available on the OTC Disclosure and News Service for the Issuer and related matters relative to its Annual Reports for the periods ended December 31, 2022 and December 31, 2023 as well as its Quarterly Reports for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024. I am not a employee of the Issuer and I have received no shares of the Issuer's stock in payment for my services. Further, I have no agreement in place to receive future shares of the Issuer's stock in payment for services and I do not own, directly or beneficially, any shares of the Issuer's securities.

This opinion is meant to apply to the laws of the United States. I am a resident of the United States and licensed to practice in the state courts of Oregon and Washington and am also admitted to practice in the U.S. District Court for the District of Oregon and in the U.S. Tax Court. I am also permitted to practice before the Securities and Exchange Commission ("SEC"), and have not been prohibited from practice thereunder. I am not now nor have I ever been the subject of an investigation, hearing or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state or foreign regulatory agency. I am not now nor have I ever been suspended or barred from practicing in any state or jurisdiction nor have I ever been charged in a civil or criminal case.

This opinion does not rely on the work of other counsel.

I have examined the corporate records, documents and such questions of law that I consider necessary or appropriate for purposes of rendering this Opinion Letter. In my review I have met with the Board of Directors and management of the Issuer and have relied upon the representations of management and officers whom I believe to be reliable sources. I have reviewed the Issuer's corporate records including the following:

- Annual Disclosure Report for the year ended December 31, 2021, (posted March 29, 2022)
- Annual Disclosure Report for the year ended December 31, 2022,

November 9, 2024

(posted November 4, 2024)

- Annual Disclosure Report for the year ended December 31, 2023, (posted November 4, 2024)
- Quarterly Disclosure Report for the period ended March 31, 2024, (posted November 4, 2024)
- Quarterly Disclosure Report for the period ended June 30, 2024, (posted November 4, 2024)
- Quarterly Disclosure Report for the period ended September 30, 2024, (posted November 4, 2024)

I have personally communicated with Xavier Mitchell, the current CEO, CFO and sole member of the Board of Directors of the Company. He has held those positions for all relevant times covered by this opinion letter except for the periods ended December 31, 2023 and March 31, 2024, when Sam Fenton served as the CEO, CFO and sole member of the Board of Directors. Mr. Fenton resigned from those positions and Mr. Mitchell was reappointed to those positions on April 1, 2024. All of the Disclosure Statements for all of these periods were prepared under the supervision and administration of Mr. Mitchell and I have discussed with him the information as posted with OTC Disclosure & News Service. All of the information I requested as a basis for this opinion has been provided to me and I believe the sources of information reviewed are reliable. In addition, I have reviewed the definition of current information set forth in SEC Rule 144(c)(2) under the Act ("Other Public Information") as well as the relevant provisions of Rule 15c2-11 of the Securities Exchange Act of 1934 (the "Exchange Act"), and the OTC Markets Group's Pink Basic Disclosure Guidelines for Providing Adequate Current Information. In my opinion, the information provided:

(A) constitutes "adequate public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) of the Act;

(B) includes all of the information that a broker-dealer would be required to obtain from the issuer to publish a quotation for the Securities under Rule 15c2-11 under the Exchange Act;

(C) complies as to form with the OTC Markets Group's Pink Basic Disclosure Guidelines for Providing Adequate Current Information, which is located at:

[www.otcmarkets.com](http://www.otcmarkets.com)

and

(D) has been posted through the OTC Disclosure and News Service.

The financial statements for the Issuer for all periods here opined on are the responsibility of the current CEO/CFO, Xavier Mitchell, of Los Angeles, CA. These financial statements have not been audited or presented as such. These Financial Statements were prepared by Xavier Mitchell. Mr. Mitchell has extensive experience managing public companies and other business interests and is well qualified by experience to prepare these statements.

The transfer agent for the Issuer is Standard Registrar & Transfer Co.,

OTC Markets Group, Inc. - p.3  
RE: Medican Enterprises, Inc.

November 9, 2024


Inc., 440 East 400 South, Suite 200, Salt Lake City, Utah 84111. The transfer agent is registered with the SEC. I have requested and obtained a copy of the shareholders' list provided to me by management and have confirmed that the number of shares issued is consistent with the corporate records of the Issuer. I have reviewed the disclosure documents currently published on otcmarkets.com for this Issuer, and have personally reviewed the information, as amended, published by the Issuer on OTC Markets News Service, and have discussed the information with management.

The Issuer represents that it is not now and has not been a "shell" corporation as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934 since October 1, 2013, when it filed a Form 8-K announcing a change from "shell" status according to Rule 12b-2 of the Exchange Act. My research of public filings supports this statement.

I have confirmed with management that management is not aware of any investigation of the Issuer or of any beneficial owner, officer, director or legal counsel of the Issuer by any federal or state regulatory authority, including the SEC for any violation of federal or state securities laws. After a review of documents as set forth above, and consultation with management, it is my opinion that the information presently being provided by the Issuer to OTC Markets Disclosure and News Service in the Financial Reports and Disclosure Information constitutes adequate current public information concerning the Issuer within the meaning of Rule 144(c)(2) of the Act.

OTC Markets, Inc., is entitled and authorized to rely upon this letter in determining whether the Issuer has made adequate information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. No person other than OTC Markets, Inc., is entitled to rely on this letter, but full permission is granted to OTC Markets, Inc., to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

Sincerely,

  
Vic Devlaeminck  
Attorney for Medican Enterprises, Inc.  
VD/wp